Condition: Multiple Myeloma · Amyloidosis · Cryoglobulinemia · Sponsor: UNC Lineberger Comprehensive Cancer Center
The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).
This description comes directly from the study's public registry record.
Nicholas Mangieri · (919) 966-4432 · nicholas_mangieri@med.unc.edu
Kendall Conder · (919) 966-4432 · kendall_conder@med.unc.edu
Always discuss trial participation with your own doctor first.
| North Carolina Cancer Hospital | Chapel Hill, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03717844